{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:47:59Z","timestamp":1792079279633,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jgar.2026.09.017","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:23:00Z","timestamp":1792077780000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eleven-year surveillance of Pseudomonas aeruginosa infections and antimicrobial resistance trends in a Portuguese tertiary hospital, 2014 - 2024: Trends and insights into novel agents"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-2940","authenticated-orcid":false,"given":"Diogo Mendes","family":"Pedro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6135-8655","authenticated-orcid":false,"given":"Maria","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Mimoso","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bruschy","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro Ayres","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlia","family":"Valadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Melo","family":"Cristino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-8554","authenticated-orcid":false,"given":"C\u00e1tia","family":"Caneiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.09.017_bib0001","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1128\/AAC.03419-14","article-title":"Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant pseudomonas aeruginosa in critically ill patients","volume":"58","author":"G\u00f3mez-Zorrilla","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0002","doi-asserted-by":"crossref","first-page":"iv32","DOI":"10.1093\/jac\/dkz285","article-title":"Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study","volume":"74","author":"McCracken","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2024.1347521","article-title":"Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal - A cross-sectional and retrospective observational study","volume":"15","author":"Mendes Pedro","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.09.017_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/tropicalmed10010026","article-title":"Risk of Colonization with Multidrug-Resistant Gram-Negative Bacteria Among Travellers and Migrants: A Narrative Review","volume":"10","author":"Mendes Pedro","year":"2025","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.jgar.2026.09.017_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.09.017_bib0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ajic.2015.01.028","article-title":"Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010","volume":"43","author":"Werth","year":"2015","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jgar.2026.09.017_bib0008","series-title":"Antimicrobial resistance surveillance in Europe 2023 - 2021 data","year":"2023"},{"key":"10.1016\/j.jgar.2026.09.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.07.003","article-title":"WHO publishes updated list of bacterial priority pathogens","volume":"5","author":"Jesudason","year":"2024","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.jgar.2026.09.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106772","article-title":"In vitro activity of ceftolozane\/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020","volume":"61","author":"Karlowsky","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.09.017_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.33.1800538","article-title":"Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU\/EEA, 2016","volume":"24","author":"Jarlier","year":"2019","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jgar.2026.09.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1017\/S095026882100042X","article-title":"COVID-19 symptoms: a case-control study, Portugal, March-April 2020","volume":"149","author":"Duque","year":"2021","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2026.09.017_bib0013","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.09.017_bib0014","first-page":"438","article-title":"Severe infections caused by difficult-to-treat Gram-negative bacteria","volume":"29","author":"Dettori","year":"2023","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jgar.2026.09.017_bib0015","first-page":"1","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","volume":"00","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.09.017_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/ofid\/ofz360.559","article-title":"Epidemiology of Carbapenem-Resistant Pseudomonas aeruginosa Identified through the Emerging Infections Program (EIP), United States, 2016-2018","volume":"6","author":"Grass","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2026.09.017_bib0017","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofin\u00f5","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/jac\/dkz030","article-title":"High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"74","author":"P\u00e9rez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fnab099","article-title":"In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study)","volume":"368","author":"Hern\u00e1ndez-Garci\u00e1","year":"2021","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jgar.2026.09.017_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmi.2022.12.006","article-title":"Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis","volume":"29","author":"Langford","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.09.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.09.017_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/mdr.2015.0218","article-title":"Selection of Amikacin Hyper-Resistant Pseudomonas aeruginosa After Stepwise Exposure to High Amikacin Concentrations","volume":"23","author":"Am\u00e1bile-Cuevas","year":"2017","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2026.09.017_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.47.19045-en","article-title":"Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe","volume":"13","author":"Souli","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2026.09.017_bib0024","first-page":"1373","article-title":"Epidemiology and high incidence of metallo-\u03b2-lactamase and AmpC-\u03b2-lactamases in nosocomial Pseudomonas aeruginosa","volume":"24","author":"Muddassir","year":"2021","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.jgar.2026.09.017_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.09.017_bib0026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2026.09.017_bib0027","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.09.017_bib0028","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","article-title":"Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study","volume":"14","author":"Bodmann","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2026.09.017_bib0029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/antibiotics10121475","article-title":"Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm","volume":"10","author":"Volpicelli","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.017_bib0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate Point-Prevalence Survey of Health Care-Associated Infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2026.09.017_bib0031","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2026.09.017_bib0032","unstructured":"European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals -2022-2023. 2024. https:\/\/doi.org\/10.2900\/88011."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:23:05Z","timestamp":1792077785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S2213716526001852"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.09.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eleven-year surveillance of Pseudomonas aeruginosa infections and antimicrobial resistance trends in a Portuguese tertiary hospital, 2014 - 2024: Trends and insights into novel agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}